Nancy Sullivan | Profiles RNS

Nancy J. Sullivan, ScD

Edward Avedisian Professor

Boston University

ScD, Harvard University
MS, Harvard University
BS, Merrimack College

Websites

	BU National Emerging Infectious Diseases Laboratories
	LinkedIn
	ResearchGate

Dr. Nancy Sullivan is the Director of the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University. She assumed the role in December of 2022, a pivotal time of heightened global awareness of the threats posed by emerging infectious diseases. While building on its outstanding record of research, she intends to steer NEIDL into the space where basic scientific discovery, translational research, pandemic preparedness, and global engagement meet.

An internationally respected leader in viral immunology, emerging diseases prevention, and infectious disease research, Dr. Sullivan previously served as chief of the Biodefense Research Section at the Vaccine Research Center (VRC) in the National Institutes of Health’s National Institute of Allergy and Infectious Disease (NIAID). She was a member of the NIAID’s Pandemic Preparedness Working Group where she proposed the protoptype pathogen approach to vaccine development [i] that is now in widespread use by national and international organizations. Dr. Sullivan was also deeply involved in the US response to COVID-19. During the pandemic, she coauthored close to 40 COVID-related research papers, covering topics as diverse as vaccine and therapeutics development and tracking of SARS-CoV-2 variant resistance to neutralization.

Beyond her work on COVID-19, Dr. Sullivan has a long-standing commitment to the study of emerging pathogens with pandemic potential including, mpox, Nipah, Ebola, Marburg, and other high consequence viruses. The global importance of her work became dramatically clear in the spring of 2014 with the multi-country outbreak of the deadly Ebola disease in West Africa. Based on years of prior research developing gene-based approaches to Ebola vaccines, Dr. Sullivan and her team were first to demonstrate vaccine protection against Ebola infection in primates, leading to development of the ChAd3-Ebola vaccine that was deployed for efficacy testing during the 2013-2016 outbreak.

Dr. Sullivan has received numerous citations for these achievements. She was named among “The Ebola Fighters” whom Time magazine awarded its Person of the Year in 2014; and in 2015, she was included in Politico’s Top 50, again for her work on Ebola. She has also received multiple NIH Director’s Awards, NIH Staff Recognition Awards, and NIAID Merit Awards, and she was a Service Service to America Medals finalist.

Modeling the role in public life she expects the NEIDL to play, Dr. Sullivan has taken her fight against emerging infectious diseases (EID) well outside her own lab. Her team developed vaccines against Marburg and Sudan viruses that have advanced to Phase I/II human clinical trials and are currently being developed by the Sabin Vaccines Institute. She also formed partnerships in the Democratic Republic of Congo (DRC) and led the discovery from a DRC Ebola survivor of a potently protective therapeutic monoclonal antibody, mAb114, that is effective in saving the lives of nearly 90% of Ebola patients who are treated soon after they contract the disease. In December of 2020, mAb114, became the NIH Vaccine Research Center’s first FDA-approved clinical product, and it is now marketed as Ebanga.

Alongside these scientific breakthroughs, Dr. Sullivan founded a scientific research and capacity building training program that is preparing scientists in the DRC to develop and fund their own independent, regionally appropriate research programs. By several years, this work anticipated global efforts of organizations like the WHO to decentralize and, at the same time, coordinate EID research.

Dr. Sullivan is a native of the Boston area. She earned her undergraduate degree at Merrimack College and doctorate at Harvard T. H. Chan School of Public Health. In 2023, Boston University appointed her the Edward Avedisian Professor and Professor of Virology, Immunology & Microbiology at the Chobanian & Avedisian School of Medicine and Professor of Biology in the College of Arts and Sciences.

Director
Boston University
National Emerging Infectious Disease Lab

Professor
Boston University Chobanian & Avedisian School of Medicine
Virology, Immunology & Microbiology

Professor
Boston University College of Arts and Sciences
Biology

BU Research
NIH RePORTER Research

Modernization of high and maximum containment research facilities at the National Emerging Infectious Diseases Laboratories (NEIDL) to meet current and future national research priorities
09/17/2024 - 05/31/2029 (PI)
NIH/Office of the Director
1C06OD037773-01

National Emerging Infectious Diseases Laboratories Operations
07/08/2021 - 06/30/2026 (PI)
NIH/National Institute of Allergy & Infectious Diseases
5UC7AI095321-11

Assays in Support of Filovirus Nonhuman Primate Studies for Advancement of Medical Countermeasures
04/14/2022 - 12/31/2025 (Subcontract PI)
Battelle Memorial Institute HHS ASPR BARDA

Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) Against BSL-4 Pathogens in NHPs
06/23/2020 - 11/28/2025 (Subcontract PI)
Battelle Memorial Institute NIH NIAID

Uncovering the RNA regulatory Mechanisms driving pathogenicity at mass-caualty viruses: Merging the technologies of RNA biology and enhanced biosafety to create the next generation of broad spectrum,
10/01/2022 - 09/30/2025 (Multi-PI)
PI: Nancy J. Sullivan, ScD
Howard Hughes Medical Institute

GLP Natural History Studies in Nonhuman Primate Models of Filovirus Infection
11/01/2023 - 09/28/2025 (Subcontract PI)
Battelle Memorial Institute HHS ASPR BARDA

Pilot Study To Assess Protection against Filovirus challenge by an infused monoclonal antibody
10/31/2019 - 08/30/2025 (Subcontract PI)
Leidos NIH NCI
75N91019D00024

Determine the Efficacy of Obeldesivir, the Oral Remdesivir Prodrug, to Mitigate od Treat Illness Caused by Nipah Virs Infection - Non-GLP
03/08/2024 - 07/31/2025 (Subcontract PI)
Battelle Memorial Institute JPEO-CBRND

Development of a Sudan ebolavirus vaccine utilizing a live vesicular stomatitis virus chimera platform: NHP Study 3
12/01/2023 - 06/30/2025 (Subcontract PI)
International AIDS Vaccine Initative Inc. HHS ASPR BARDA

Restricted: Pilot Study To Assess Protection against Filovirus challenge by an infused monoclonal antibody
10/31/2019 - 06/16/2025 (Subcontract PI)
Leidos NIH NCI
75N91019D00024

Showing 10 of 17 results. Show All Results

Title

Yr	Title	Project-Sub Proj
2023	Nipah virus vaccines and monoclonal antibodies	1ZIAAI005168-02
2023	Monkeypox vaccines and monoclonal antibodies	1ZIAAI005167-02
2023	Ebola Vaccine Immune Correlates and Mechanism of Protection	1ZIAAI005082-19
2023	Ebola Vaccine Development	1ZIAAI005079-19
2023	mAbs and vaccines against SARS CoV-2	1ZIAAI005145-04
2023	Marburg Vaccine Development	1ZIAAI005080-19
2022	Ebola Vaccine Development	1ZIAAI005079-18
2022	Marburg Vaccine Development	1ZIAAI005080-18
2022	Yeast Engineering Technology & Immunobiology Core	1ZIAAI005142-04
2022	mAbs and vaccines against SARS CoV-2	1ZIAAI005145-03

Showing 10 of 81 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Misasi J, Wei RR, Wang L, Pegu A, Wei CJ, Oloniniyi OK, Zhou T, Moliva JI, Zhao B, Choe M, Yang ES, Zhang Y, Boruszczak M, Chen M, Leung K, Li J, Yang ZY, Andersen H, Carlton K, Godbole S, Harris DR, Henry AR, Ivleva VB, Lei QP, Liu C, Longobardi L, Merriam JS, Nase D, Olia AS, Pessaint L, Porto M, Shi W, Wallace SM, Wolff JJ, Douek DC, Suthar MS, Gall JG, Koup RA, Kwong PD, Mascola JR, Nabel GJ, Sullivan NJ. A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo. Sci Transl Med. 2024 Oct 09; 16(768):eado9026.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 39383243

Mucker EM, Freyn AW, Bixler SL, Cizmeci D, Atyeo C, Earl PL, Natarajan H, Santos G, Frey TR, Levin RH, Meni A, Arunkumar GA, Stadlbauer D, Jorquera PA, Bennett H, Johnson JC, Hardcastle K, Americo JL, Cotter CA, Koehler JW, Davis CI, Shamblin JD, Ostrowski K, Raymond JL, Ricks KM, Carfi A, Yu WH, Sullivan NJ, Moss B, Alter G, Hooper JW. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell. 2024 Oct 03; 187(20):5540-5553.e10. PMID: 39236707

Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole Á, Wawina-Bokalanga T, Mukadi-Bamuleka D, Amuri-Aziza A, Malyamungu-Bubala N, Mweshi-Kumbana F, Mutimbwa-Mambo L, Belesi-Siangoli F, Mujula Y, Parker E, Muswamba-Kayembe PC, Nundu SS, Lushima RS, Makangara-Cigolo JC, Mulopo-Mukanya N, Pukuta-Simbu E, Akil-Bandali P, Kavunga H, Abdramane O, Brosius I, Bangwen E, Vercauteren K, Sam-Agudu NA, Mills EJ, Tshiani-Mbaya O, Hoff NA, Rimoin AW, Hensley LE, Kindrachuk J, Baxter C, de Oliveira T, Ayouba A, Peeters M, Delaporte E, Ahuka-Mundeke S, Mohr EL, Sullivan NJ, Muyembe-Tamfum JJ, Nachega JB, Rambaut A, Liesenborghs L, Mbala-Kingebeni P. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat Med. 2024 Oct; 30(10):2791-2795. PMID: 38871006; PMCID: PMC11485229; DOI: 10.1038/s41591-024-03130-3;

Nachega JB, Sam-Agudu NA, Ogoina D, Mbala-Kingebeni P, Ntoumi F, Nakouné E, Njouom R, Lewis RF, Gandhi M, Rosenthal PJ, Rawat A, Wilson LA, Kindrachuk J, Liesenborghs L, Mills EJ, Preiser W, Rimoin AW, Sullivan NJ, Peeters M, Delaporte E, Baxter C, Harrison L, Hermans MP, Mohr EL, Gonsalves G, Ndembi N, Zumla A, Muyembe-Tamfum JJ. The surge of mpox in Africa: a call for action. Lancet Glob Health. 2024 Jul; 12(7):e1086-e1088. PMID: 38735300

Happe M, Hofstetter AR, Wang J, Yamshchikov GV, Holman LA, Novik L, Strom L, Kiweewa F, Wakabi S, Millard M, Kelley CF, Kabbani S, Edupuganti S, Beck A, Kaltovich F, Murray T, Tsukerman S, Carr D, Ashman C, Stanley DA, Ploquin A, Bailer RT, Schwartz R, Cham F, Tindikahwa A, Hu Z, Gordon IJ, Rouphael N, Houser KV, Coates EE, Graham BS, Koup RA, Mascola JR, Sullivan NJ, Robb ML, Ake JA, Lyke KE, Mulligan MJ, Ledgerwood JE, Kibuuka H. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials. NPJ Vaccines. 2024 Mar 29; 9(1):67. PMID: 38553525; PMCID: PMC10980745; DOI: 10.1038/s41541-024-00833-z;

Honko AN, Hunegnaw R, Moliva JI, Ploquin A, Dulan CNM, Murray T, Carr D, Foulds KE, Geisbert JB, Geisbert TW, Johnson JC, Wollen-Roberts SE, Trefry JC, Stanley DA, Sullivan NJ. A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure. bioRxiv. 2024 Feb 12.View Related Profiles.

Honko, Anna
Sullivan, Nancy

PMID: 38410448; PMCID: PMC10896339; DOI: 10.1101/2024.02.07.579118;

Xu D, Powell AE, Utz A, Sanyal M, Do J, Patten JJ, Moliva JI, Sullivan NJ, Davey RA, Kim PS. Design of universal Ebola virus vaccine candidates via immunofocusing. Proc Natl Acad Sci U S A. 2024 Feb 13; 121(7):e2316960121.View Related Profiles.

Sullivan, Nancy
Davey, Robert

PMID: 38319964; PMCID: PMC10873634; DOI: 10.1073/pnas.2316960121;

Sankhala RS, Lal KG, Jensen JL, Dussupt V, Mendez-Rivera L, Bai H, Wieczorek L, Mayer SV, Zemil M, Wagner DA, Townsley SM, Hajduczki A, Chang WC, Chen WH, Donofrio GC, Jian N, King HAD, Lorang CG, Martinez EJ, Rees PA, Peterson CE, Schmidt F, Hart TJ, Duso DK, Kummer LW, Casey SP, Williams JK, Kannan S, Slike BM, Smith L, Swafford I, Thomas PV, Tran U, Currier JR, Bolton DL, Davidson E, Doranz BJ, Hatziioannou T, Bieniasz PD, Paquin-Proulx D, Reiley WW, Rolland M, Sullivan NJ, Vasan S, Collins ND, Modjarrad K, Gromowski GD, Polonis VR, Michael NL, Krebs SJ, Joyce MG. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques. Nat Commun. 2024 Jan 03; 15(1):200. PMID: 38172512; PMCID: PMC10764318; DOI: 10.1038/s41467-023-44265-0;

Moliva JI, Andrew SF, Flynn BJ, Wagner DA, Foulds KE, Gagne M, Flebbe DR, Lamb E, Provost S, Marquez J, Mychalowych A, Lorag CG, Honeycutt CC, Burnett MR, McCormick L, Henry AR, Godbole S, Davis-Gardner ME, Minai M, Bock KW, Nagata BM, Todd JM, McCarthy E, Dodson A, Kouneski K, Cook A, Pessaint L, Ry AV, Valentin D, Young S, Littman Y, Boon ACM, Suthar MS, Lewis MG, Andersen H, Alves DA, Woodward R, Leuzzi A, Vitelli A, Colloca S, Folgori A, Raggiolli A, Capone S, Nason MC, Douek DC, Roederer M, Seder RA, Sullivan NJ. Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates. bioRxiv. 2023 Nov 22. PMID: 38076895; PMCID: PMC10705562; DOI: 10.1101/2023.11.22.567930;

Dupuy LC, Spiropoulou CF, Towner JS, Spengler JR, Sullivan NJ, Montgomery JM. Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation. J Infect Dis. 2023 Oct 18; 228(Suppl 6):S446-S459. PMID: 37849404; PMCID: PMC11009505; DOI: 10.1093/infdis/jiad362;

Showing 10 of 158 results. Show More

Xu D, Powell AE, Utz A, Sanyal M, Do J, Patten JJ, Moliva JI, Sullivan NJ, Davey RA, Kim PS. Design of universal Ebola virus vaccine candidates via immunofocusing. bioRxiv. 2023 Oct 17.View Related Profiles.

Sullivan, Nancy
Davey, Robert

PMID: 37904982; PMCID: PMC10614775; DOI: 10.1101/2023.10.14.562364;

Freyn AW, Atyeo C, Earl PL, Americo JL, Chuang GY, Natarajan H, Frey TR, Gall JG, Moliva JI, Hunegnaw R, Asthagiri Arunkumar G, Ogega CO, Nasir A, Santos G, Levin RH, Meni A, Jorquera PA, Bennett H, Johnson JA, Durney MA, Stewart-Jones G, Hooper JW, Colpitts TM, Alter G, Sullivan NJ, Carfi A, Moss B. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci Transl Med. 2023 Oct 04; 15(716):eadg3540. PMID: 37792954

Mwesigwa B, Houser KV, Hofstetter AR, Ortega-Villa AM, Naluyima P, Kiweewa F, Nakabuye I, Yamshchikov GV, Andrews C, O'Callahan M, Strom L, Schech S, Anne Eller L, Sondergaard EL, Scott PT, Amare MF, Modjarrad K, Wamala A, Tindikahwa A, Musingye E, Nanyondo J, Gaudinski MR, Gordon IJ, Holman LA, Saunders JG, Costner PJM, Mendoza FH, Happe M, Morgan P, Plummer SH, Hickman SP, Vazquez S, Murray T, Cordon J, Dulan CNM, Hunegnaw R, Basappa M, Padilla M, Gajjala SR, Swanson PA, Lin BC, Coates EE, Gall JG, McDermott AB, Koup RA, Mascola JR, Ploquin A, Sullivan NJ, Kibuuka H, Ake JA, Ledgerwood JE. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial. Lancet Infect Dis. 2023 Dec; 23(12):1408-1417. PMID: 37544326; PMCID: PMC10837320; DOI: 10.1016/S1473-3099(23)00344-4;

Hamer MJ, Houser KV, Hofstetter AR, Ortega-Villa AM, Lee C, Preston A, Augustine B, Andrews C, Yamshchikov GV, Hickman S, Schech S, Hutter JN, Scott PT, Waterman PE, Amare MF, Kioko V, Storme C, Modjarrad K, McCauley MD, Robb ML, Gaudinski MR, Gordon IJ, Holman LA, Widge AT, Strom L, Happe M, Cox JH, Vazquez S, Stanley DA, Murray T, Dulan CNM, Hunegnaw R, Narpala SR, Swanson PA, Basappa M, Thillainathan J, Padilla M, Flach B, O'Connell S, Trofymenko O, Morgan P, Coates EE, Gall JG, McDermott AB, Koup RA, Mascola JR, Ploquin A, Sullivan NJ, Ake JA, Ledgerwood JE. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet. 2023 Jan 28; 401(10373):294-302. PMID: 36709074; PMCID: PMC10127441; DOI: 10.1016/S0140-6736(22)02400-X;

Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, Johnson SR, Imundo LF, Winthrop KL, Arasaratnam RJ, Baden LR, Berard R, Bridges SL, Cheah JTL, Curtis JR, Ferguson PJ, Hakkarinen I, Onel KB, Schultz G, Sivaraman V, Smith BJ, Sparks JA, Vogel TP, Williams EA, Calabrese C, Cunha JS, Fontanarosa J, Gillispie-Taylor MC, Gkrouzman E, Iyer P, Lakin KS, Legge A, Lo MS, Lockwood MM, Sadun RE, Singh N, Sullivan N, Tam H, Turgunbaev M, Turner AS, Reston J. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023 Mar; 75(3):449-464. PMID: 36597813; PMCID: PMC10291822; DOI: 10.1002/acr.25045;

Lima NS, Musayev M, Johnston TS, Wagner DA, Henry AR, Wang L, Yang ES, Zhang Y, Birungi K, Black WP, O'Dell S, Schmidt SD, Moon D, Lorang CG, Zhao B, Chen M, Boswell KL, Roberts-Torres J, Davis RL, Peyton L, Narpala SR, O'Connell S, Serebryannyy L, Wang J, Schrager A, Talana CA, Shimberg G, Leung K, Shi W, Khashab R, Biber A, Zilberman T, Rhein J, Vetter S, Ahmed A, Novik L, Widge A, Gordon I, Guech M, Teng IT, Phung E, Ruckwardt TJ, Pegu A, Misasi J, Doria-Rose NA, Gaudinski M, Koup RA, Kwong PD, McDermott AB, Amit S, Schacker TW, Levy I, Mascola JR, Sullivan NJ, Schramm CA, Douek DC. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. Nat Commun. 2022 Dec 14; 13(1):7733.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 36517467; PMCID: PMC9748393; DOI: 10.1038/s41467-022-35456-2;

Hunegnaw R, Honko AN, Wang L, Carr D, Murray T, Shi W, Nguyen L, Storm N, Dulan CNM, Foulds KE, Agans KN, Cross RW, Geisbert JB, Cheng C, Ploquin A, Stanley DA, Geisbert TW, Nabel GJ, Sullivan NJ. A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. Sci Transl Med. 2022 Dec 14; 14(675):eabq6364.View Related Profiles.

Honko, Anna
Storm, Nadia
Sullivan, Nancy

PMID: 36516269; DOI: 10.1126/scitranslmed.abq6364;

Misasi J, Wei RR, Wang L, Pegu A, Wei CJ, Oloniniyi OK, Zhou T, Moliva JI, Zhao B, Choe M, Yang ES, Zhang Y, Boruszczak M, Chen M, Leung K, Li J, Yang ZY, Andersen H, Carlton K, Godbole S, Harris DR, Henry AR, Ivleva VB, Lei P, Liu C, Longobardi L, Merriam JS, Nase D, Olia AS, Pessaint L, Porto M, Shi W, Wolff JJ, Douek DC, Suthar MS, Gall J, Koup RA, Kwong PD, Mascola JR, Nabel GJ, Sullivan NJ. A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization. bioRxiv. 2022 Nov 21.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 35982683; PMCID: PMC9387125; DOI: 10.1101/2022.07.29.502029;

Finch CL, King TH, Alfson KJ, Albanese KA, Smith JNP, Smock P, Jakubik J, Goez-Gazi Y, Gazi M, Dutton JW, Clemmons EA, Mattix ME, Carrion R, Rudge T, Ridenour A, Woodin SF, Hunegnaw R, Sullivan NJ, Xu R. Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs. Vaccines (Basel). 2022 Nov 15; 10(11). PMID: 36423030; PMCID: PMC9694189; DOI: 10.3390/vaccines10111935;

Cross RW, Longini IM, Becker S, Bok K, Boucher D, Carroll MW, Díaz JV, Dowling WE, Draghia-Akli R, Duworko JT, Dye JM, Egan MA, Fast P, Finan A, Finch C, Fleming TR, Fusco J, Geisbert TW, Griffiths A, Günther S, Hensley LE, Honko A, Hunegnaw R, Jakubik J, Ledgerwood J, Luhn K, Matassov D, Meshulam J, Nelson EV, Parks CL, Rustomjee R, Safronetz D, Schwartz LM, Smith D, Smock P, Sow Y, Spiropoulou CF, Sullivan NJ, Warfield KL, Wolfe D, Woolsey C, Zahn R, Henao-Restrepo AM, Muñoz-Fontela C, Marzi A. An introduction to the Marburg virus vaccine consortium, MARVAC. PLoS Pathog. 2022 Oct; 18(10):e1010805.View Related Profiles.

Honko, Anna
Griffiths, Anthony
Nelson, Emily
Sullivan, Nancy

PMID: 36227853; PMCID: PMC9560149; DOI: 10.1371/journal.ppat.1010805;

Finch CL, Dowling WE, King TH, Martinez C, Nguyen BV, Roozendaal R, Rustomjee R, Skiadopoulos MH, Vert-Wong E, Yellowlees A, Sullivan NJ. Bridging Animal and Human Data in Pursuit of Vaccine Licensure. Vaccines (Basel). 2022 Aug 25; 10(9). PMID: 36146462; PMCID: PMC9503666; DOI: 10.3390/vaccines10091384;

Tiemessen MM, Solforosi L, Dekking L, Czapska-Casey D, Serroyen J, Sullivan NJ, Volkmann A, Pau MG, Callendret B, Schuitemaker H, Luhn K, Zahn R, Roozendaal R. Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels. Vaccines (Basel). 2022 Aug 05; 10(8). PMID: 36016151; PMCID: PMC9412258; DOI: 10.3390/vaccines10081263;

Lima NS, Musayev M, Johnston TS, Wagner DA, Henry AR, Wang L, Yang ES, Zhang Y, Birungi K, Black WP, O'Dell S, Schmidt SD, Moon D, Lorang CG, Zhao B, Chen M, Boswell KL, Roberts-Torres J, Davis RL, Peyton L, Narpala SR, O'Connell S, Wang J, Schrager A, Talana CA, Leung K, Shi W, Khashab R, Biber A, Zilberman T, Rhein J, Vetter S, Ahmed A, Novik L, Widge A, Gordon I, Guech M, Teng IT, Phung E, Ruckwardt TJ, Pegu A, Misasi J, Doria-Rose NA, Gaudinski M, Koup RA, Kwong PD, McDermott AB, Amit S, Schacker TW, Levy I, Mascola JR, Sullivan NJ, Schramm CA, Douek DC. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. bioRxiv. 2022 Jun 30.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 35378757; PMCID: PMC8978934; DOI: 10.1101/2022.03.28.486152;

Teng IT, Nazzari AF, Choe M, Liu T, Oliveira de Souza M, Petrova Y, Tsybovsky Y, Wang S, Zhang B, Artamonov M, Madan B, Huang A, Lopez Acevedo SN, Pan X, Ruckwardt TJ, DeKosky BJ, Mascola JR, Misasi J, Sullivan NJ, Zhou T, Kwong PD. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. PLoS One. 2022; 17(5):e0268767.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 35609088; PMCID: PMC9129042; DOI: 10.1371/journal.pone.0268767;

Westendorf K, Žentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, Lovett E, van der Lee R, Hendle J, Pustilnik A, Sauder JM, Kraft L, Hwang Y, Siegel RW, Chen J, Heinz BA, Higgs RE, Kallewaard NL, Jepson K, Goya R, Smith MA, Collins DW, Pellacani D, Xiang P, de Puyraimond V, Ricicova M, Devorkin L, Pritchard C, O'Neill A, Dalal K, Panwar P, Dhupar H, Garces FA, Cohen CA, Dye JM, Huie KE, Badger CV, Kobasa D, Audet J, Freitas JJ, Hassanali S, Hughes I, Munoz L, Palma HC, Ramamurthy B, Cross RW, Geisbert TW, Menachery V, Lokugamage K, Borisevich V, Lanz I, Anderson L, Sipahimalani P, Corbett KS, Yang ES, Zhang Y, Shi W, Zhou T, Choe M, Misasi J, Kwong PD, Sullivan NJ, Graham BS, Fernandez TL, Hansen CL, Falconer E, Mascola JR, Jones BE, Barnhart BC. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022 May 17; 39(7):110812.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 35568025; PMCID: PMC9035363; DOI: 10.1016/j.celrep.2022.110812;

Zhou T, Wang L, Misasi J, Pegu A, Zhang Y, Harris DR, Olia AS, Talana CA, Yang ES, Chen M, Choe M, Shi W, Teng IT, Creanga A, Jenkins C, Leung K, Liu T, Stancofski ED, Stephens T, Zhang B, Tsybovsky Y, Graham BS, Mascola JR, Sullivan NJ, Kwong PD. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science. 2022 Apr 22; 376(6591):eabn8897.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 35324257; PMCID: PMC9580340; DOI: 10.1126/science.abn8897;

Pandian V, Dino MJS, McLennan L, Brown KM, Sullivan N, Coker D, Pandian OBR, Matta HR, Davidson P, Szanton SL. Nursing education in uncharted waters: Are we successfully navigating the industrial revolutions ahead? J Clin Nurs. 2022 Sep; 31(17-18):e26-e28. PMID: 35411638

DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, Alter G, Amara RR, Baric RS, Barouch DH, Bloom JD, Bloyet LM, Bonenfant G, Boon ACM, Boritz EA, Bratt DL, Bricker TL, Brown L, Buchser WJ, Carreño JM, Cohen-Lavi L, Darling TL, Davis-Gardner ME, Dearlove BL, Di H, Dittmann M, Doria-Rose NA, Douek DC, Drosten C, Edara VV, Ellebedy A, Fabrizio TP, Ferrari G, Fischer WM, Florence WC, Fouchier RAM, Franks J, García-Sastre A, Godzik A, Gonzalez-Reiche AS, Gordon A, Haagmans BL, Halfmann PJ, Ho DD, Holbrook MR, Huang Y, James SL, Jaroszewski L, Jeevan T, Johnson RM, Jones TC, Joshi A, Kawaoka Y, Kercher L, Koopmans MPG, Korber B, Koren E, Koup RA, LeGresley EB, Lemieux JE, Liebeskind MJ, Liu Z, Livingston B, Logue JP, Luo Y, McDermott AB, McElrath MJ, Meliopoulos VA, Menachery VD, Montefiori DC, Mühlemann B, Munster VJ, Munt JE, Nair MS, Netzl A, Niewiadomska AM, O'Dell S, Pekosz A, Perlman S, Pontelli MC, Rockx B, Rolland M, Rothlauf PW, Sacharen S, Scheuermann RH, Schmidt SD, Schotsaert M, Schultz-Cherry S, Seder RA, Sedova M, Sette A, Shabman RS, Shen X, Shi PY, Shukla M, Simon V, Stumpf S, Sullivan NJ, Thackray LB, Theiler J, Thomas PG, Trifkovic S, Türeli S, Turner SA, Vakaki MA, van Bakel H, VanBlargan LA, Vincent LR, Wallace ZS, Wang L, Wang M, Wang P, Wang W, Weaver SC, Webby RJ, Weiss CD, Wentworth DE, Weston SM, Whelan SPJ, Whitener BM, Wilks SH, Xie X, Ying B, Yoon H, Zhou B, Hertz T, Smith DJ, Diamond MS, Post DJ, Suthar MS. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022 May; 605(7911):640-652. PMID: 35361968; PMCID: PMC9345323; DOI: 10.1038/s41586-022-04690-5;

Lee HK, Knabl L, Moliva JI, Knabl L, Werner AP, Boyoglu-Barnum S, Kapferer S, Pateter B, Walter M, Sullivan NJ, Furth PA, Hennighausen L. mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron. Cell Rep. 2022 Apr 12; 39(2):110680. PMID: 35395191; PMCID: PMC8947943; DOI: 10.1016/j.celrep.2022.110680;

Gagne M, Moliva JI, Foulds KE, Andrew SF, Flynn BJ, Werner AP, Wagner DA, Teng IT, Lin BC, Moore C, Jean-Baptiste N, Carroll R, Foster SL, Patel M, Ellis M, Edara VV, Maldonado NV, Minai M, McCormick L, Honeycutt CC, Nagata BM, Bock KW, Dulan CNM, Cordon J, Flebbe DR, Todd JM, McCarthy E, Pessaint L, Van Ry A, Narvaez B, Valentin D, Cook A, Dodson A, Steingrebe K, Nurmukhambetova ST, Godbole S, Henry AR, Laboune F, Roberts-Torres J, Lorang CG, Amin S, Trost J, Naisan M, Basappa M, Willis J, Wang L, Shi W, Doria-Rose NA, Zhang Y, Yang ES, Leung K, O'Dell S, Schmidt SD, Olia AS, Liu C, Harris DR, Chuang GY, Stewart-Jones G, Renzi I, Lai YT, Malinowski A, Wu K, Mascola JR, Carfi A, Kwong PD, Edwards DK, Lewis MG, Andersen H, Corbett KS, Nason MC, McDermott AB, Suthar MS, Moore IN, Roederer M, Sullivan NJ, Douek DC, Seder RA. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell. 2022 Apr 28; 185(9):1556-1571.e18. PMID: 35447072; PMCID: PMC8947944; DOI: 10.1016/j.cell.2022.03.038;

Westendorf K, Žentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, Lovett E, van der Lee R, Hendle J, Pustilnik A, Sauder JM, Kraft L, Hwang Y, Siegel RW, Chen J, Heinz BA, Higgs RE, Kallewaard NL, Jepson K, Goya R, Smith MA, Collins DW, Pellacani D, Xiang P, de Puyraimond V, Ricicova M, Devorkin L, Pritchard C, O'Neill A, Dalal K, Panwar P, Dhupar H, Garces FA, Cohen CA, Dye JM, Huie KE, Badger CV, Kobasa D, Audet J, Freitas JJ, Hassanali S, Hughes I, Munoz L, Palma HC, Ramamurthy B, Cross RW, Geisbert TW, Menacherry V, Lokugamage K, Borisevich V, Lanz I, Anderson L, Sipahimalani P, Corbett KS, Yang ES, Zhang Y, Shi W, Zhou T, Choe M, Misasi J, Kwong PD, Sullivan NJ, Graham BS, Fernandez TL, Hansen CL, Falconer E, Mascola JR, Jones BE, Barnhart BC. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv. 2022 Mar 24.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 33972947; PMCID: PMC8109210; DOI: 10.1101/2021.04.30.442182;

Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, Tang H, Manning KE, Edara VV, Lai L, Ellis M, Moore KM, Floyd K, Foster SL, Posavad CM, Atmar RL, Lyke KE, Zhou T, Wang L, Zhang Y, Gaudinski MR, Black WP, Gordon I, Guech M, Ledgerwood JE, Misasi JN, Widge A, Sullivan NJ, Roberts PC, Beigel JH, Korber B, Baden LR, El Sahly H, Chalkias S, Zhou H, Feng J, Girard B, Das R, Aunins A, Edwards DK, Suthar MS, Mascola JR, Montefiori DC. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. N Engl J Med. 2022 Mar 17; 386(11):1088-1091.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 35081298; PMCID: PMC8809504; DOI: 10.1056/NEJMc2119912;

Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, Darling TL, Joshi A, Loeber S, Singh G, Foster SL, Ying B, Case JB, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio JE, Hernandez-Ortiz JP, Henry AR, Ciuoderis K, Florek KR, Patel M, Odle A, Wong LR, Bateman AC, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche AS, Sordillo EM, Chang LA, van Bakel H, Simon V, Douek DC, Sullivan NJ, Thackray LB, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby RJ, Seder RA, Suthar MS, García-Sastre A, Schotsaert M, Suzuki T, Boon ACM, Diamond MS, Kawaoka Y. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. 2022 Mar; 603(7902):687-692. PMID: 35062015; PMCID: PMC8942849; DOI: 10.1038/s41586-022-04441-6;

Richardson SI, Manamela NP, Motsoeneng BM, Kaldine H, Ayres F, Makhado Z, Mennen M, Skelem S, Williams N, Sullivan NJ, Misasi J, Gray GG, Bekker LG, Ueckermann V, Rossouw TM, Boswell MT, Ntusi NAB, Burgers WA, Moore PL. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep Med. 2022 Feb 15; 3(2):100510.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 35233544; PMCID: PMC8761540; DOI: 10.1016/j.xcrm.2022.100510;

Misasi, John
Sullivan, Nancy

PMID: 35018379; PMCID: PMC8750702; DOI: 10.1101/2021.12.29.474491;

Diamond M, Halfmann P, Maemura T, Iwatsuki-Horimoto K, Iida S, Kiso M, Scheaffer S, Darling T, Joshi A, Loeber S, Foster S, Ying B, Whitener B, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Li R, Sakai Y, Liu Y, Larson D, Osorio J, Hernandez-Ortiz J, Ciuoderis K, Florek K, Patel M, Bateman A, Odle A, Wong LY, Wang Z, Edara VV, Chong Z, Thackray L, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby R, Seder R, Suthar M, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon A, Kawaoka Y, Douek D, Moliva J, Sullivan N, Gagne M, Ransier A, Case J, Jeevan T, Franks J, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Singh G, Warang P, Gonzalez-Reiche AS, Sordillo E, van Bakel H, Simon V. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq. 2021 Dec 29. PMID: 34981044; PMCID: PMC8722607; DOI: 10.21203/rs.3.rs-1211792/v1;

Gagne M, Corbett KS, Flynn BJ, Foulds KE, Wagner DA, Andrew SF, Todd JM, Honeycutt CC, McCormick L, Nurmukhambetova ST, Davis-Gardner ME, Pessaint L, Bock KW, Nagata BM, Minai M, Werner AP, Moliva JI, Tucker C, Lorang CG, Zhao B, McCarthy E, Cook A, Dodson A, Teng IT, Mudvari P, Roberts-Torres J, Laboune F, Wang L, Goode A, Kar S, Boyoglu-Barnum S, Yang ES, Shi W, Ploquin A, Doria-Rose N, Carfi A, Mascola JR, Boritz EA, Edwards DK, Andersen H, Lewis MG, Suthar MS, Graham BS, Roederer M, Moore IN, Nason MC, Sullivan NJ, Douek DC, Seder RA. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell. 2022 Jan 06; 185(1):113-130.e15. PMID: 34921774; PMCID: PMC8639396; DOI: 10.1016/j.cell.2021.12.002;

Vergara FH, Budhathoki C, Sheridan DJ, Davis JE, Sullivan NJ. Predictors for Telephone Outreach Post-hospital Discharge. Prof Case Manag. 2021 Nov-Dec 01; 26(6):286-297. PMID: 34609341; DOI: 10.1097/NCM.0000000000000530;

Gagne M, Corbett KS, Flynn BJ, Foulds KE, Wagner DA, Andrew SF, Todd JM, Honeycutt CC, McCormick L, Nurmukhambetova ST, Davis-Gardner ME, Pessaint L, Bock KW, Nagata BM, Minai M, Werner AP, Moliva JI, Tucker C, Lorang CG, Zhao B, McCarthy E, Cook A, Dodson A, Mudvari P, Roberts-Torres J, Laboune F, Wang L, Goode A, Kar S, Boyoglu-Barnum S, Yang ES, Shi W, Ploquin A, Doria-Rose N, Carfi A, Mascola JR, Boritz EA, Edwards DK, Andersen H, Lewis MG, Suthar MS, Graham BS, Roederer M, Moore IN, Nason MC, Sullivan NJ, Douek DC, Seder RA. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway. bioRxiv. 2021 Oct 24. PMID: 34729558; PMCID: PMC8562540; DOI: 10.1101/2021.10.23.465542;

Corbett KS, Gagne M, Wagner DA, O' Connell S, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham CD, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O'Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Yang ES, Wang L, Choe M, Boyoglu-Barnum S, Wei S, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd JM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, Seder RA. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science. 2021 Dec 10; 374(6573):1343-1353.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 34672695; DOI: 10.1126/science.abl8912;

Corbett KS, Nason MC, Flach B, Gagne M, O'Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, McDanal C, Francica JR, Flynn B, Wu K, Choi A, Koch M, Abiona OM, Werner AP, Moliva JI, Andrew SF, Donaldson MM, Fintzi J, Flebbe DR, Lamb E, Noe AT, Nurmukhambetova ST, Provost SJ, Cook A, Dodson A, Faudree A, Greenhouse J, Kar S, Pessaint L, Porto M, Steingrebe K, Valentin D, Zouantcha S, Bock KW, Minai M, Nagata BM, van de Wetering R, Boyoglu-Barnum S, Leung K, Shi W, Yang ES, Zhang Y, Todd JM, Wang L, Alvarado GS, Andersen H, Foulds KE, Edwards DK, Mascola JR, Moore IN, Lewis MG, Carfi A, Montefiori D, Suthar MS, McDermott A, Roederer M, Sullivan NJ, Douek DC, Graham BS, Seder RA. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021 Sep 17; 373(6561):eabj0299. PMID: 34529476; PMCID: PMC8449013; DOI: 10.1126/science.abj0299;

Corbett KS, Werner AP, Connell SO, Gagne M, Lai L, Moliva JI, Flynn B, Choi A, Koch M, Foulds KE, Andrew SF, Flebbe DR, Lamb E, Nurmukhambetova ST, Provost SJ, Bock KW, Minai M, Nagata BM, Ry AV, Flinchbaugh Z, Johnston TS, Mokhtari EB, Mudvari P, Henry AR, Laboune F, Chang B, Porto M, Wear J, Alvarado GS, Boyoglu-Barnum S, Todd JM, Bart B, Cook A, Dodson A, Pessaint L, Steingrebe K, Elbashir S, Sriparna M, Pekosz A, Andersen H, Wu K, Edwards DK, Kar S, Lewis MG, Boritz E, Moore IN, Carfi A, Suthar MS, McDermott A, Roederer M, Nason MC, Sullivan NJ, Douek DC, Graham BS, Seder RA. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nat Immunol. 2021 Oct; 22(10):1306-1315. PMID: 34417590; PMCID: PMC8488000; DOI: 10.1038/s41590-021-01021-0;

Corbett KS, Gagne M, Wagner DA, Connell SO, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham C, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O'Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Wang L, Choe M, Boyoglu-Barnum S, Shi W, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd JM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, Seder RA. Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates. bioRxiv. 2021 Aug 12.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 34426813; PMCID: PMC8382125; DOI: 10.1101/2021.08.11.456015;

Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, Gagne M, Johnston TS, Tucker C, Davis RL, Flach B, O'Connell S, Andrew SF, Lamb E, Flebbe DR, Nurmukhambetova ST, Donaldson MM, Todd JM, Zhu AL, Atyeo C, Fischinger S, Gorman MJ, Shin S, Edara VV, Floyd K, Lai L, Boyoglu-Barnum S, Van De Wetering R, Tylor A, McCarthy E, Lecouturier V, Ruiz S, Berry C, Tibbitts T, Andersen H, Cook A, Dodson A, Pessaint L, Van Ry A, Koutsoukos M, Gutzeit C, Teng IT, Zhou T, Li D, Haynes BF, Kwong PD, McDermott A, Lewis MG, Fu TM, Chicz R, van der Most R, Corbett KS, Suthar MS, Alter G, Roederer M, Sullivan NJ, Douek DC, Graham BS, Casimiro D, Seder RA. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci Transl Med. 2021 Aug 18; 13(607). PMID: 34315825; PMCID: PMC9266840; DOI: 10.1126/scitranslmed.abi4547;

DiPiazza AT, Leist SR, Abiona OM, Moliva JI, Werner A, Minai M, Nagata BM, Bock KW, Phung E, Schäfer A, Dinnon KH, Chang LA, Loomis RJ, Boyoglu-Barnum S, Alvarado GS, Sullivan NJ, Edwards DK, Morabito KM, Mascola JR, Carfi A, Corbett KS, Moore IN, Baric RS, Graham BS, Ruckwardt TJ. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity. 2021 Aug 10; 54(8):1869-1882.e6. PMID: 34270939; PMCID: PMC8249710; DOI: 10.1016/j.immuni.2021.06.018;

Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, Pegu A, Oloniniyi OK, Henry AR, Darko S, Narpala SR, Hatcher C, Martinez DR, Tsybovsky Y, Phung E, Abiona OM, Antia A, Cale EM, Chang LA, Choe M, Corbett KS, Davis RL, DiPiazza AT, Gordon IJ, Hait SH, Hermanus T, Kgagudi P, Laboune F, Leung K, Liu T, Mason RD, Nazzari AF, Novik L, O'Connell S, O'Dell S, Olia AS, Schmidt SD, Stephens T, Stringham CD, Talana CA, Teng IT, Wagner DA, Widge AT, Zhang B, Roederer M, Ledgerwood JE, Ruckwardt TJ, Gaudinski MR, Moore PL, Doria-Rose NA, Baric RS, Graham BS, McDermott AB, Douek DC, Kwong PD, Mascola JR, Sullivan NJ, Misasi J. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 34210892; PMCID: PMC9269068; DOI: 10.1126/science.abh1766;

Condy E, Kaat AJ, Becker L, Sullivan N, Soorya L, Berger N, Berry-Kravis E, Michalak C, Thurm A. A novel measure of matching categories for early development: Item creation and pilot feasibility study. Res Dev Disabil. 2021 Aug; 115:103993. PMID: 34049209; PMCID: PMC8750168; DOI: 10.1016/j.ridd.2021.103993;

Corbett KS, Werner AP, O' Connell S, Gagne M, Lai L, Moliva JI, Flynn B, Choi A, Koch M, Foulds KE, Andrew SF, Flebbe DR, Lamb E, Nurmukhambetova ST, Provost SJ, Bock KW, Minai M, Nagata BM, Van Ry A, Flinchbaugh Z, Johnston TS, Mokhtari EB, Mudvari P, Henry AR, Laboune F, Chang B, Porto M, Wear J, Alvarado GS, Boyoglu-Barnum S, Todd JM, Bart B, Cook A, Dodson A, Pessaint L, Steingrebe K, Elbashir S, Andersen H, Wu K, Edwards DK, Kar S, Lewis MG, Bortiz E, Moore IN, Carfi A, Suthar MS, McDermott A, Roederer M, Nason MC, Sullivan NJ, Douek DC, Graham BS, Seder RA. Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates. bioRxiv. 2021 May 24. PMID: 34075375; PMCID: PMC8168383; DOI: 10.1101/2021.05.21.445189;

Corbett KS, Nason MC, Flach B, Gagne M, O' Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, McDanal C, Francica JR, Flynn B, Wu K, Choi A, Koch M, Abiona OM, Werner AP, Alvarado GS, Andrew SF, Donaldson MM, Fintzi J, Flebbe DR, Lamb E, Noe AT, Nurmukhambetova ST, Provost SJ, Cook A, Dodson A, Faudree A, Greenhouse J, Kar S, Pessaint L, Porto M, Steingrebe K, Valentin D, Zouantcha S, Bock KW, Minai M, Nagata BM, Moliva JI, van de Wetering R, Boyoglu-Barnum S, Leung K, Shi W, Yang ES, Zhang Y, Todd JM, Wang L, Andersen H, Foulds KE, Edwards DK, Mascola JR, Moore IN, Lewis MG, Carfi A, Montefiori D, Suthar MS, McDermott A, Sullivan NJ, Roederer M, Douek DC, Graham BS, Seder RA. Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates. bioRxiv. 2021 Apr 23. PMID: 33907752; PMCID: PMC8077626; DOI: 10.1101/2021.04.20.440647;

Ko SH, Bayat Mokhtari E, Mudvari P, Stein S, Stringham CD, Wagner D, Ramelli S, Ramos-Benitez MJ, Strich JR, Davey RT, Zhou T, Misasi J, Kwong PD, Chertow DS, Sullivan NJ, Boritz EA. High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. PLoS Pathog. 2021 Apr; 17(4):e1009431.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 33831133; PMCID: PMC8031304; DOI: 10.1371/journal.ppat.1009431;

Mukhamedova M, Wrapp D, Shen CH, Gilman MSA, Ruckwardt TJ, Schramm CA, Ault L, Chang L, Derrien-Colemyn A, Lucas SAM, Ransier A, Darko S, Phung E, Wang L, Zhang Y, Rush SA, Madan B, Stewart-Jones GBE, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Doria-Rose NA, Morabito KM, DeKosky BJ, Gaudinski MR, Chen GL, Crank MC, Misasi J, Sullivan NJ, Douek DC, Kwong PD, Graham BS, McLellan JS, Mascola JR. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity. 2021 Apr 13; 54(4):769-780.e6.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 33823129; PMCID: PMC8099422; DOI: 10.1016/j.immuni.2021.03.004;

Mbala-Kingebeni P, Pratt C, Mutafali-Ruffin M, Pauthner MG, Bile F, Nkuba-Ndaye A, Black A, Kinganda-Lusamaki E, Faye M, Aziza A, Diagne MM, Mukadi D, White B, Hadfield J, Gangavarapu K, Bisento N, Kazadi D, Nsunda B, Akonga M, Tshiani O, Misasi J, Ploquin A, Epaso V, Sana-Paka E, N'kasar YTT, Mambu F, Edidi F, Matondo M, Bula Bula J, Diallo B, Keita M, Belizaire MRD, Fall IS, Yam A, Mulangu S, Rimion AW, Salfati E, Torkamani A, Suchard MA, Crozier I, Hensley L, Rambaut A, Faye O, Sall A, Sullivan NJ, Bedford T, Andersen KG, Wiley MR, Ahuka-Mundeke S, Muyembe Tamfum JJ. Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease. N Engl J Med. 2021 Apr 01; 384(13):1240-1247.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 33789012; PMCID: PMC7888312; DOI: 10.1056/NEJMoa2024670;

Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021 Apr 15; 384(15):1468-1470. PMID: 33730471; PMCID: PMC8008744; DOI: 10.1056/NEJMc2102179;

Misasi J, Sullivan NJ. Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. Immunity. 2021 Mar 09; 54(3):412-436.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 33691133; DOI: 10.1016/j.immuni.2021.01.015;

Marcus H, Thompson E, Zhou Y, Bailey M, Donaldson MM, Stanley DA, Asiedu C, Foulds KE, Roederer M, Moliva JI, Sullivan NJ. Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates. Front Immunol. 2021; 12:627688. PMID: 33790899; PMCID: PMC8006325; DOI: 10.3389/fimmu.2021.627688;

Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, Gagne M, Johnston TS, Tucker C, Davis RL, Flach B, O'Connell S, Andrew SF, Lamb E, Flebbe DR, Nurmukhambetova ST, Donaldson MM, Todd JM, Zhu AL, Atyeo C, Fischinger S, Gorman MJ, Shin S, Edara VV, Floyd K, Lai L, Tylor A, McCarthy E, Lecouturier V, Ruiz S, Berry C, Tibbitts T, Andersen H, Cook A, Dodson A, Pessaint L, Ry AV, Koutsoukos M, Gutzeit C, Teng IT, Zhou T, Li D, Haynes BF, Kwong PD, McDermott A, Lewis MG, Fu TM, Chicz R, van der Most R, Corbett KS, Suthar MS, Alter G, Roederer M, Sullivan NJ, Douek DC, Graham BS, Casimiro D, Seder RA. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates. bioRxiv. 2021 Mar 02. PMID: 33688652; PMCID: PMC7941623; DOI: 10.1101/2021.03.02.433390;

Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, Pegu A, Oloninyi OK, Ransier A, Darko S, Narpala SR, Hatcher C, Martinez DR, Tsybovsky Y, Phung E, Abiona OM, Cale EM, Chang LA, Corbett KS, DiPiazza AT, Gordon IJ, Leung K, Liu T, Mason RD, Nazzari A, Novik L, Olia AS, Doria-Rose NA, Stephens T, Stringham CD, Talana CA, Teng IT, Wagner D, Widge AT, Zhang B, Roederer M, Ledgerwood JE, Ruckwardt TJ, Gaudinski MR, Baric RS, Graham BS, McDermott AB, Douek DC, Kwong PD, Mascola JR, Sullivan NJ, Misasi J. Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. bioRxiv. 2021 Mar 01.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 33655252; PMCID: PMC7924272; DOI: 10.1101/2021.02.25.432969;

Ko SH, Mokhtari EB, Mudvari P, Stein S, Stringham CD, Wagner D, Ramelli S, Ramos-Benitez MJ, Strich JR, Davey RT, Zhou T, Misasi J, Kwong PD, Chertow DS, Sullivan NJ, Boritz EA. High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19. bioRxiv. 2021 Feb 22.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 33655255; PMCID: PMC7924285; DOI: 10.1101/2021.02.21.432184;

Zhang B, Chao CW, Tsybovsky Y, Abiona OM, Hutchinson GB, Moliva JI, Olia AS, Pegu A, Phung E, Stewart-Jones GBE, Verardi R, Wang L, Wang S, Werner A, Yang ES, Yap C, Zhou T, Mascola JR, Sullivan NJ, Graham BS, Corbett KS, Kwong PD. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci Rep. 2020 Oct 23; 10(1):18149. PMID: 33097791; PMCID: PMC7584627; DOI: 10.1038/s41598-020-74949-2;

Zhou T, Teng IT, Olia AS, Cerutti G, Gorman J, Nazzari A, Shi W, Tsybovsky Y, Wang L, Wang S, Zhang B, Zhang Y, Katsamba PS, Petrova Y, Banach BB, Fahad AS, Liu L, Lopez Acevedo SN, Madan B, Oliveira de Souza M, Pan X, Wang P, Wolfe JR, Yin M, Ho DD, Phung E, DiPiazza A, Chang LA, Abiona OM, Corbett KS, DeKosky BJ, Graham BS, Mascola JR, Misasi J, Ruckwardt T, Sullivan NJ, Shapiro L, Kwong PD. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Rep. 2020 Oct 27; 33(4):108322.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 33091382; PMCID: PMC7550166; DOI: 10.1016/j.celrep.2020.108322;

Perretta JS, Duval-Arnould J, Poling S, Sullivan N, Jeffers JM, Farrow L, Shilkofski NA, Brown KM, Hunt EA. Best Practices and Theoretical Foundations for Simulation Instruction Using Rapid-Cycle Deliberate Practice. Simul Healthc. 2020 Oct; 15(5):356-362. PMID: 32809977

Zhang B, Chao CW, Tsybovsky Y, Abiona OM, Hutchinson GB, Moliva JI, Olia AS, Pegu A, Phung E, Stewart-Jones G, Verardi R, Wang L, Wang S, Werner A, Yang ES, Yap C, Zhou T, Mascola JR, Sullivan NJ, Graham BS, Corbett KS, Kwong PD. A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone. bioRxiv. 2020 Aug 22. PMID: 32676596; PMCID: PMC7359518; DOI: 10.1101/2020.06.11.147496;

Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N, Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin BC, Louder MK, O'Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd JM, Pessaint L, Van Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell TA, Cook A, Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K, Zhou T, Teng IT, Widge A, Gordon I, Novik L, Gillespie RA, Loomis RJ, Moliva JI, Stewart-Jones G, Himansu S, Kong WP, Nason MC, Morabito KM, Ruckwardt TJ, Ledgerwood JE, Gaudinski MR, Kwong PD, Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore IN, Sullivan NJ, Roederer M, Seder RA, Graham BS. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 Oct 15; 383(16):1544-1555. PMID: 32722908; PMCID: PMC7449230; DOI: 10.1056/NEJMoa2024671;

Zhou T, Teng IT, Olia AS, Cerutti G, Gorman J, Nazzari A, Shi W, Tsybovsky Y, Wang L, Wang S, Zhang B, Zhang Y, Katsamba PS, Petrova Y, Banach BB, Fahad AS, Liu L, Acevedo SNL, Madan B, de Souza MO, Pan X, Wang P, Wolfe JR, Yin M, Ho DD, Phung E, DiPiazza A, Chang L, Abiona O, Corbett KS, DeKosky BJ, Graham BS, Mascola JR, Misasi J, Ruckwardt T, Sullivan NJ, Shapiro L, Kwong PD. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. SSRN. 2020 Jul 21; 3639618.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 32742241; PMCID: PMC7385481; DOI: 10.2139/ssrn.3639618;

Zhou T, Teng IT, Olia AS, Cerutti G, Gorman J, Nazzari A, Shi W, Tsybovsky Y, Wang L, Wang S, Zhang B, Zhang Y, Katsamba PS, Petrova Y, Banach BB, Fahad AS, Liu L, Lopez Acevedo SN, Madan B, de Souza MO, Pan X, Wang P, Wolfe JR, Yin M, Ho DD, Phung E, DiPiazza A, Chang L, Abiona O, Corbett KS, DeKosky BJ, Graham BS, Mascola JR, Misasi J, Ruckwardt T, Sullivan NJ, Shapiro L, Kwong PD. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. bioRxiv. 2020 Jun 23.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 32596696; PMCID: PMC7315997; DOI: 10.1101/2020.06.22.166033;

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 10; 71(10):1599-1613.View Related Profiles.

Dubreuil, Maureen
Sullivan, Nancy

PMID: 31436036; PMCID: PMC6764882; DOI: 10.1002/art.41042;

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 10; 71(10):1285-1299.View Related Profiles.

Dubreuil, Maureen
Sullivan, Nancy

PMID: 31436026; PMCID: PMC6764857; DOI: 10.1002/acr.24025;

Vergara FH, Davis JE, Budhathoki C, Sullivan NJ, Sheridan DJ. Face-to-Face Meetings with Neurosurgical Patients Before Hospital Discharge: Impact on Telephone Outreach, Emergency Department Visits, and Hospital Readmissions. Popul Health Manag. 2020 Apr; 23(2):174-182. PMID: 31343380; PMCID: PMC7074889; DOI: 10.1089/pop.2019.0038;

Sutton MS, Ellis-Connell A, Balgeman AJ, Barry G, Weiler AM, Hetzel SJ, Zhou Y, Lau-Kilby AW, Mason RD, Biris KK, Mascola JR, Sullivan NJ, Roederer M, Friedrich TC, O'Connor SL. CD8ß Depletion Does Not Prevent Control of Viral Replication or Protection from Challenge in Macaques Chronically Infected with a Live Attenuated Simian Immunodeficiency Virus. J Virol. 2019 Aug 01; 93(15). PMID: 31092584; PMCID: PMC6639280; DOI: 10.1128/JVI.00537-19;

Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 02; 393(10174):889-898.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 30686586; PMCID: PMC6436835; DOI: 10.1016/S0140-6736(19)30036-4;

Cagigi A, Ploquin A, Niezold T, Zhou Y, Tsybovsky Y, Misasi J, Sullivan NJ. Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction. J Infect Dis. 2018 Nov 22; 218(suppl_5):S537-S544.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 30137549; PMCID: PMC6249595; DOI: 10.1093/infdis/jiy450;

Cagigi A, Misasi J, Ploquin A, Stanley DA, Ambrozak D, Tsybovsky Y, Mason RD, Roederer M, Sullivan NJ. Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures. J Infect Dis. 2018 Nov 22; 218(suppl_5):S528-S536.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 30010811; PMCID: PMC6455927; DOI: 10.1093/infdis/jiy333;

Foronda CL, Swoboda SM, Henry MN, Kamau E, Sullivan N, Hudson KW. Student preferences and perceptions of learning from vSIM for Nursing™. Nurse Educ Pract. 2018 Nov; 33:27-32. PMID: 30223110

Ploquin A, Zhou Y, Sullivan NJ. Ebola Immunity: Gaining a Winning Position in Lightning Chess. J Immunol. 2018 Aug 01; 201(3):833-842. PMID: 30038036; DOI: 10.4049/jimmunol.1700827;

Mulangu S, Alfonso VH, Hoff NA, Doshi RH, Mulembakani P, Kisalu NK, Okitolonda-Wemakoy E, Kebela BI, Marcus H, Shiloach J, Phue JN, Wright LL, Muyembe-Tamfum JJ, Sullivan NJ, Rimoin AW. Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo. J Infect Dis. 2018 Jan 30; 217(4):529-537. PMID: 29329455; PMCID: PMC5853806; DOI: 10.1093/infdis/jix619;

Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE, Niezold T, Choi CW, Viox EG, Fahad A, Cagigi A, Ploquin A, Leung K, Yang ES, Kong WP, Voss WN, Schmidt AG, Moody MA, Ambrozak DR, Henry AR, Laboune F, Ledgerwood JE, Graham BS, Connors M, Douek DC, Sullivan NJ, Ellington AD, Mascola JR, Georgiou G. Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Nat Biotechnol. 2018 Feb; 36(2):152-155.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 29309060; PMCID: PMC5801115; DOI: 10.1038/nbt.4052;

Vergara FH, Sullivan NJ, Sheridan DJ, Davis JE. The Best Practice for Increasing Telephone Outreach: An Integrative Review. Prof Case Manag. 2018; 23(6):307-317. PMID: 30289857; DOI: 10.1097/NCM.0000000000000296;

Beroz S, Sullivan N, Kramasz V, Morgan P. The Multiple-Patient Simulation Toolkit: Purpose, Process, and Pilot. Nurs Educ Perspect. 2018; 39(3):180-181. PMID: 29256993

Graham BS, Sullivan NJ. Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. Nat Immunol. 2018 Jan; 19(1):20-28. PMID: 29199281; PMCID: PMC7097586; DOI: 10.1038/s41590-017-0007-9;

Liang F, Lindgren G, Sandgren KJ, Thompson EA, Francica JR, Seubert A, De Gregorio E, Barnett S, O'Hagan DT, Sullivan NJ, Koup RA, Seder RA, Loré K. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci Transl Med. 2017 Jun 07; 9(393). PMID: 28592561; DOI: 10.1126/scitranslmed.aal2094;

Zou Z, Misasi J, Sullivan N, Sun PD. Overexpression of Ebola virus envelope GP1 protein. Protein Expr Purif. 2017 Jul; 135:45-53.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 28458053; PMCID: PMC5549271; DOI: 10.1016/j.pep.2017.04.010;

Sullivan N, Swoboda S, M Davidson P. [Not Available]. Soins. 2017 Mar; 62(813):58. PMID: 28342474

Vergara FH, Sheridan DJ, Sullivan NJ, Budhathoki C. Improving Posthospital Discharge Telephone Reach Rates Through Prehospital Discharge Face-to-Face Meetings. Prof Case Manag. 2017; 22(6):275-283. PMID: 29016418; DOI: 10.1097/NCM.0000000000000243;

Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016 Mar 18; 351(6279):1343-6.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 26917592; PMCID: PMC5241105; DOI: 10.1126/science.aad6117;

Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18; 351(6279):1339-42.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 26917593; DOI: 10.1126/science.aad5224;

Ploquin A, Leigh K, Sullivan NJ. Plotkin SA, Oreintein WA, Offit PA (eds.), Vaccines. Chapter 20: Ebola Vaccines. Elsevier Global Book Production. 2016.

De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016 Mar; 16(3):311-20. PMID: 26725450; DOI: 10.1016/S1473-3099(15)00486-7;

Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny MP, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AVS, Ballou WR, Sullivan N, Graham B, Levine MM. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016 Jan; 16(1):31-42. PMID: 26546548; PMCID: PMC4700389; DOI: 10.1016/S1473-3099(15)00362-X;

Ledgerwood JE, Sullivan NJ, Graham BS. Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. N Engl J Med. 2015 Aug 20; 373(8):776. PMID: 26287857; DOI: 10.1056/NEJMc1505499;

Zhou Y, Sullivan NJ. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Curr Opin Immunol. 2015 Aug; 35:131-6. PMID: 26247875; DOI: 10.1016/j.coi.2015.06.006;

Liang F, Ploquin A, Hernández JD, Fausther-Bovendo H, Lindgren G, Stanley D, Martinez AS, Brenchley JM, Koup RA, Loré K, Sullivan NJ. Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques. J Immunol Methods. 2015 Oct; 425:69-78. PMID: 26099800; PMCID: PMC4604051; DOI: 10.1016/j.jim.2015.06.011;

Sullivan N. An integrative review: instructional strategies to improve nurses' retention of cardiopulmonary resuscitation priorities. Int J Nurs Educ Scholarsh. 2015 Apr 01; 12. PMID: 25830906

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT, Thomas SJ. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 Jan 26; 376(4):330-341. PMID: 25830322; PMCID: PMC5408576; DOI: 10.1056/NEJMoa1414216;

Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med. 2016 Apr 28; 374(17):1635-46. PMID: 25629663; PMCID: PMC5798586; DOI: 10.1056/NEJMoa1411627;

Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GJ, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015 Apr 18; 385(9977):1545-54. PMID: 25540891; DOI: 10.1016/S0140-6736(14)62385-0;

Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS. Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med. 2017 Mar 09; 376(10):928-938. PMID: 25426834; DOI: 10.1056/NEJMoa1410863;

Sullivan NJ, Duval-Arnould J, Twilley M, Smith SP, Aksamit D, Boone-Guercio P, Jeffries PR, Hunt EA. Simulation exercise to improve retention of cardiopulmonary resuscitation priorities for in-hospital cardiac arrests: A randomized controlled trial. Resuscitation. 2015 Jan; 86:6-13. PMID: 25447038; DOI: 10.1016/j.resuscitation.2014.10.021;

Misasi J, Sullivan NJ. Camouflage and misdirection: the full-on assault of ebola virus disease. Cell. 2014 Oct 23; 159(3):477-86.View Related Profiles.

Misasi, John
Sullivan, Nancy

PMID: 25417101; PMCID: PMC4243531; DOI: 10.1016/j.cell.2014.10.006;

Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST. Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses. 2014 Sep; 6(9):3663-82.View Related Profiles.

Honko, Anna
Griffiths, Anthony
Muhlberger, Elke
Olinger, Gene
Sullivan, Nancy
Davey, Robert

PMID: 25256396; PMCID: PMC4189044; DOI: 10.3390/v6093663;

Reed PE, Mulangu S, Cameron KN, Ondzie AU, Joly D, Bermejo M, Rouquet P, Fabozzi G, Bailey M, Shen Z, Keele BF, Hahn B, Karesh WB, Sullivan NJ. A new approach for monitoring ebolavirus in wild great apes. PLoS Negl Trop Dis. 2014 Sep; 8(9):e3143. PMID: 25232832; PMCID: PMC4169258; DOI: 10.1371/journal.pntd.0003143;

Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015 Feb 15; 211(4):549-57. PMID: 25225676; PMCID: PMC4318920; DOI: 10.1093/infdis/jiu511;

Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicosia A, Cortese R, Koup RA, Sullivan NJ. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014 Oct; 20(10):1126-9.View Related Profiles.

Honko, Anna
Sullivan, Nancy

PMID: 25194571; DOI: 10.1038/nm.3702;

Paris R, Kuschner RA, Binn L, Thomas SJ, Colloca S, Nicosia A, Cortese R, Bailer RT, Sullivan N, Koup RA. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. Clin Vaccine Immunol. 2014 May; 21(5):783-6. PMID: 24623627

Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol. 2014 May; 159(5):1229-37.View Related Profiles.

Honko, Anna
Muhlberger, Elke
Olinger, Gene
Brauburger, Kristina
Sullivan, Nancy
Davey, Robert

PMID: 24190508; PMCID: PMC4010566; DOI: 10.1007/s00705-013-1877-2;

Shekelle PG, Wachter RM, Pronovost PJ, Schoelles K, McDonald KM, Dy SM, Shojania K, Reston J, Berger Z, Johnsen B, Larkin JW, Lucas S, Martinez K, Motala A, Newberry SJ, Noble M, Pfoh E, Ranji SR, Rennke S, Schmidt E, Shanman R, Sullivan N, Sun F, Tipton K, Treadwell JR, Tsou A, Vaiana ME, Weaver SJ, Wilson R, Winters BD. Making health care safer II: an updated critical analysis of the evidence for patient safety practices. Evid Rep Technol Assess (Full Rep). 2013 Mar; (211):1-945. PMID: 24423049

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Lofts LL, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST. Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol. 2013 Jun; 158(6):1425-32.View Related Profiles.

Honko, Anna
Muhlberger, Elke
Olinger, Gene
Sullivan, Nancy
Davey, Robert

PMID: 23358612; PMCID: PMC3669655; DOI: 10.1007/s00705-012-1594-2;

Limperopoulos C, Chilingaryan G, Sullivan N, Guizard N, Robertson RL, du Plessis AJ. Injury to the premature cerebellum: outcome is related to remote cortical development. Cereb Cortex. 2014 Mar; 24(3):728-36. PMID: 23146968

Bolduc ME, du Plessis AJ, Sullivan N, Guizard N, Zhang X, Robertson RL, Limperopoulos C. Regional cerebellar volumes predict functional outcome in children with cerebellar malformations. Cerebellum. 2012 Jun; 11(2):531-42. PMID: 21901523

Fausther-Bovendo H, Mulangu S, Sullivan NJ. Ebolavirus vaccines for humans and apes. Curr Opin Virol. 2012 Jun; 2(3):324-9. PMID: 22560007; PMCID: PMC3397659; DOI: 10.1016/j.coviro.2012.04.003;

Misasi J, Chandran K, Yang JY, Considine B, Filone CM, Côté M, Sullivan N, Fabozzi G, Hensley L, Cunningham J. Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol. 2012 Mar; 86(6):3284-92.View Related Profiles.

Filone, Claire Marie
Misasi, John
Sullivan, Nancy

PMID: 22238307; PMCID: PMC3302294; DOI: 10.1128/JVI.06346-11;

Forbes TJ, Kim DW, Du W, Turner DR, Holzer R, Amin Z, Hijazi Z, Ghasemi A, Rome JJ, Nykanen D, Zahn E, Cowley C, Hoyer M, Waight D, Gruenstein D, Javois A, Foerster S, Kreutzer J, Sullivan N, Khan A, Owada C, Hagler D, Lim S, Canter J, Zellers T. Comparison of surgical, stent, and balloon angioplasty treatment of native coarctation of the aorta: an observational study by the CCISC (Congenital Cardiovascular Interventional Study Consortium). J Am Coll Cardiol. 2011 Dec 13; 58(25):2664-74. PMID: 22152954

Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011 Sep; 17(9):1128-31.View Related Profiles.

Honko, Anna
Olinger, Gene
Sullivan, Nancy

PMID: 21857654; DOI: 10.1038/nm.2447;

Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011 May; 85(9):4222-33.View Related Profiles.

Honko, Anna
Sullivan, Nancy

PMID: 21325402; PMCID: PMC3126236; DOI: 10.1128/JVI.02407-10;

Fabozzi G, Nabel CS, Dolan MA, Sullivan NJ. Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J Virol. 2011 Mar; 85(6):2512-23. PMID: 21228243; PMCID: PMC3067942; DOI: 10.1128/JVI.01160-10;

Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010 Dec 16; 29(2):304-13. PMID: 21034824

Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, Sullivan NJ. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol. 2010 Oct; 84(19):10386-94. PMID: 20660192; PMCID: PMC2937810; DOI: 10.1128/JVI.00594-10;

Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 2010 May 20; 6(5):e1000904.View Related Profiles.

Honko, Anna
Sullivan, Nancy

PMID: 20502688; PMCID: PMC2873919; DOI: 10.1371/journal.ppat.1000904;

Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology. 2010 Jun 05; 401(2):228-35. PMID: 20304456; PMCID: PMC3351102; DOI: 10.1016/j.virol.2010.02.029;

Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009 May; 7(5):393-400. PMID: 19369954; PMCID: PMC7097244; DOI: 10.1038/nrmicro2129;

Rao S, Bryant M, Herbert R, Sullivan N, Murray C, Bacher J, Safdar N. Idiopathic chondrolysis condition in two young, wild-caught Cynomolgus monkeys (Macaca fascicularis) reared in captivity. Vet Pathol. 2009 May; 46(3):509-13. PMID: 19176502

Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol. 2007 Nov; 8(11):1159-64. PMID: 17952040; PMCID: PMC7097212; DOI: 10.1038/ni1519;

Suliman SG, Gurlek A, Byrne JV, Sullivan N, Thanabalasingham G, Cudlip S, Ansorge O, Wass JA. Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features. J Clin Endocrinol Metab. 2007 Oct; 92(10):3829-35. PMID: 17623759

Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 2007 Jan; 3(1):e9. PMID: 17238286; PMCID: PMC1779296; DOI: 10.1371/journal.ppat.0030009;

Sullivan NJ, Nabel GJ. Plotkin SA, Orenstein WA (eds.), Vaccines. Ebola Vaccine. WB Saunders Company - Harcourt Brace. 2007.

Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006 Nov; 13(11):1267-77. PMID: 16988008; PMCID: PMC1656552; DOI: 10.1128/CVI.00162-06;

Yu JS, Liao HX, Gerdon AE, Huffman B, Scearce RM, McAdams M, Alam SM, Popernack PM, Sullivan NJ, Wright D, Cliffel DE, Nabel GJ, Haynes BF. Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. J Virol Methods. 2006 Nov; 137(2):219-28. PMID: 16857271; DOI: 10.1016/j.jviromet.2006.06.014;

Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006 Jun; 3(6):e177. PMID: 16683867; PMCID: PMC1459482; DOI: 10.1371/journal.pmed.0030177;

Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005 Jul; 11(7):786-90. PMID: 15937495; DOI: 10.1038/nm1258;

Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science. 2005 Jun 10; 308(5728):1643-5. PMID: 15831716; PMCID: PMC4797943; DOI: 10.1126/science.1110656;

Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, Nabel E, Nabel GJ. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol. 2005 Jan; 79(1):547-53. PMID: 15596847; PMCID: PMC538691; DOI: 10.1128/JVI.79.1.547-553.2005;

Nabel GJ, Sullivan NJ, Yang ZY. Klenk HD Feldmann H, (eds.) Ebola and Marburg Viruses: Molecular and Cellular Biology. Cellular and molecular mechanisms of Ebola pathogenicity and approaches to vaccine developmen. Horizon Bioscience. 2004.

Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol. 2003 Sep; 77(18):9733-7. PMID: 12941881

Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003 Aug 07; 424(6949):681-4. PMID: 12904795; PMCID: PMC7095492; DOI: 10.1038/nature01876;

Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol. 2001; 260:145-69. PMID: 11443872

Sullivan NJ. Burton D (ed.), Contemporary Topics in Microbiology and Immunology. Antibody enhancement of viral infection. Springer-Verlag. 2001.

Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000 Nov 30; 408(6812):605-9. PMID: 11117750

Nabel GJ, Sullivan NJ. Antibodies and resistance to natural HIV infection. N Engl J Med. 2000 Oct 26; 343(17):1263-5. PMID: 11071680

Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000 Aug; 6(8):886-9. PMID: 10932225

Sullivan N, Sun Y, Binley J, Lee J, Barbas CF, Parren PW, Burton DR, Sodroski J. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol. 1998 Aug; 72(8):6332-8. PMID: 9658072

Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, Gershoni J, Robinson J, Moore J, Sodroski J. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol. 1998 Jun; 72(6):4694-703. PMID: 9573233

Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, Wyatt R, Sodroski J. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol. 1997 Dec; 71(12):9808-12. PMID: 9371651

Farzan M, Choe H, Martin K, Marcon L, Hofmann W, Karlsson G, Sun Y, Barrett P, Marchand N, Sullivan N, Gerard N, Gerard C, Sodroski J. Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med. 1997 Aug 04; 186(3):405-11. PMID: 9236192

Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, Mackay CR. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997 May 05; 185(9):1681-91. PMID: 9151905

Binley JM, Ditzel HJ, Barbas CF, Sullivan N, Sodroski J, Parren PW, Burton DR. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses. 1996 Jul 01; 12(10):911-24. PMID: 8798976

Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996 Jun 28; 85(7):1135-48. PMID: 8674119

Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996 Feb; 70(2):1100-8. PMID: 8551569

Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol. 1995 Jul; 69(7):4413-22. PMID: 7769703

Ditzel HJ, Binley JM, Moore JP, Sodroski J, Sullivan N, Sawyer LS, Hendry RM, Yang WP, Barbas CF, Burton DR. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J Immunol. 1995 Jan 15; 154(2):893-906. PMID: 7529290

Ohl CA, Sullivan N, Paparello S. Streptococcus sanguis bacteremia during ciprofloxacin therapy of a diabetic foot ulcer. Am J Med. 1994 May; 96(5):482-3. PMID: 8192181

Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon SW, Fung MS, Traincard F, Pinkus M, et al. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J Virol. 1993 Oct; 67(10):6136-51. PMID: 7690418

Wyatt R, Sullivan N, Thali M, Repke H, Ho D, Robinson J, Posner M, Sodroski J. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol. 1993 Aug; 67(8):4557-65. PMID: 8331723

McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, et al. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol. 1993 Aug; 67(8):4932-44. PMID: 7687306

Sullivan N, Thali M, Furman C, Ho DD, Sodroski J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol. 1993 Jun; 67(6):3674-9. PMID: 8497077

Bergeron L, Sullivan N, Sodroski J. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus. J Virol. 1992 Apr; 66(4):2389-97. PMID: 1548769

Sullivan NJ, Lautens LL, Tashjian AH. Solubilization of receptors for thyrotropin-releasing hormone from GH4C1 rat pituitary cells: demonstration of guanyl nucleotide sensitivity. Mol Endocrinol. 1987 Dec; 1(12):889-98. PMID: 2856405

Kim K, Pickering LK, DuPont HL, Sullivan N, Wilkins T. In vitro and in vivo neutralizing activity of human colostrum and milk against purified toxins A and B of Clostridium difficile. J Infect Dis. 1984 Jul; 150(1):57-62. PMID: 6747345

Goldberg RJ, Tull R, Sullivan N, Wallace S, Wool M. Defining discipline roles in consultation psychiatry: the multidisciplinary team approach to psychosocial oncology. Gen Hosp Psychiatry. 1984 Jan; 6(1):17-23. PMID: 6693025

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 158 publications over 32 distinct years, with a maximum of 24 publications in 2021

Bar chart showing 158 publications over 32 distinct years, with a maximum of 24 publications in 2021

Year	Publications
1984	2
1987	1
1992	1
1993	4
1994	1
1995	2
1996	3
1997	3
1998	2
2000	3
2001	2
2003	2
2004	1
2005	3
2006	3
2007	4
2009	2
2010	4
2011	4
2012	4
2013	3
2014	9
2015	8
2016	3
2017	5
2018	8
2019	5
2020	7
2021	24
2022	19
2023	8
2024	8

Media Mentions

Recent (within 3 months)

The Second Trump White House Could Drastically Reshape Infectious Disease Research. Here’s What’s at Stake.

ProPublica 1/15/2025

Older

BU’s Leading Home for Infectious Diseases Research to Get Major Upgrade with NIH Grant

BU Today 10/29/2024

ModeX's multispecific antibodies shut down COVID variants and advance to the clinic with $35M more BARDA bucks

Fierce Biotech 10/9/2024

Deadly Marburg virus: scientists race to test vaccines in outbreak

Nature 10/1/2024

Five Faculty Receive Edward Avedisian Professorships

BU Today 3/21/2024

Preventing the Next Pandemic

BU Today 11/15/2023

New Marburg Outbreaks in Africa Raise Alarm About the Deadly Virus’s Spread

The New York Times 4/3/2023

A rare Marburg outbreak sparks a race against time to test vaccines and drugs

STAT 2/14/2023

Nancy J. Sullivan, Ebola Vaccine and Treatment Pioneer, Named New NEIDL Director

BU Today 9/16/2022

Why the Work of Dr. Nancy J. Sullivan Could Be Key to a Potential Ebola Vaccine

The Wall Street Journal 10/20/2014

2022 National Institutes of Health: NIH Director’s Award

2021 National Institutes of Health: NIH Director’s Award

2020 National Institute of Allergy and Infectious Diseases: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission,

2020 National Institutes of Health,: Special Act Award

2020 Service to America Medals: People’s Choice Award (Finalist)

2019 National Institute of Allergy and Infectious Diseases: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission

2019 Science Magazine: Breakthrough of the Year (top ten nominated)

2018 National Institute of Allergy and Infectious Diseases, Vaccine Research Center: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission

2018 Office of Technology Transfer, National Institutes of Health: Philip S. Chen Distinguished Lecture on Innovation and Technology Transfer

2017 Merrimack College: Honorary Doctorate

2016 Federal Laboratory Consortium for Technology Transfer (FLC): Excellence in Technology Transfer Award

2015 National Institutes of Health: NIH Director’s Award

2015 Politico Magazine: The Politico Top 50

2014 TIME: Time Person of the Year: Ebola Fighters, Time Magazine, for Research on Ebola virus vaccines

2011 National Institute of Allergy and Infectious Diseases,: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission

Contact for Mentoring:

620 Albany St
Boston MA 02118
Google Map

Download vCard

Sullivan's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (500) concept(s)